Literature DB >> 27129979

Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan.

Eiji Yamada1, Seishi Tsunoda2, Tsuyoshi Abe3, Eri Uchida4, Hiromichi Teraoka5, Seitaro Watanabe1, Ichiro Kawana1, Masataka Tagri6, Noriomi Hosaka7, Kazuki Nagai8, Haruo Nishino9, Atsushi Nakajima10.   

Abstract

BACKGROUND: Some patients with irritable bowel syndrome (IBS) show poor response to treatment. However, risk factors associated with poor therapeutic response have not been determined.
METHODS: This multicenter trial evaluated consecutive outpatients with IBS undergoing treatment for more than 1 month. Mental health status and physical function were evaluated using the Japanese version of the SF-8. Therapeutic response was evaluated using the IBS severity index-Japanese version (IBS-SIJ). Patients with IBS-SIJ scores ≥175 were defined as poor responders to treatment, whereas those with IBS-SIJ scores <175 were defined as good responders. The demographic and clinical characteristics of these two groups, along with medications, were compared.
RESULTS: The study enrolled 131 participants, 75 with IBS-SIJ scores ≥175-56 with IBS-SIJ scores <175. Multiple logistic regression analysis showed that female sex [odds ratio (OR) 2.67, 95 % confidence interval (CI) 1.19-5.97, p = 0.0167] and mental component summary (MCS) of the SF-8 <40 (OR 2.58, 95 % CI 1.12-5.97, p = 0.0263) were independent risk factors for poor therapeutic response in patients with IBS.
CONCLUSIONS: Lower MCS and female sex were risk factors for poor therapeutic response in patients with IBS. Ascertaining the mechanisms by which lower MCS and female sex are associated with poor therapeutic response in IBS may help design better treatments (Trial registration number: UMIN000016804).

Entities:  

Keywords:  Irritable bowel syndrome; Mental health; Poor therapeutic response

Mesh:

Substances:

Year:  2016        PMID: 27129979     DOI: 10.1007/s00535-016-1215-z

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  21 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

2.  Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study.

Authors:  Smita L S Halder; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; L Joseph Melton; Nicholas J Talley
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

3.  Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life.

Authors:  Makiko Kaji; Yasuhiro Fujiwara; Masatsugu Shiba; Yukie Kohata; Hirokazu Yamagami; Tetsuya Tanigawa; Kenji Watanabe; Toshio Watanabe; Kazunari Tominaga; Tetsuo Arakawa
Journal:  J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 4.029

4.  Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.

Authors:  Tom Kennedy; Roger Jones; Simon Darnley; Paul Seed; Simon Wessely; Trudie Chalder
Journal:  BMJ       Date:  2005-08-10

5.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.

Authors:  C Y Francis; J Morris; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

Review 6.  Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors.

Authors:  Filippo Cremonini; Nicholas J Talley
Journal:  Gastroenterol Clin North Am       Date:  2005-06       Impact factor: 3.806

Review 7.  Cross-national epidemiology of depression and gender.

Authors:  T B Ustün
Journal:  J Gend Specif Med       Date:  2000 Mar-Apr

8.  Prevalence and severity of mental health-related disability and relationship to diagnosis.

Authors:  Kristy Sanderson; Gavin Andrews
Journal:  Psychiatr Serv       Date:  2002-01       Impact factor: 3.084

9.  Evidence-based clinical practice guidelines for irritable bowel syndrome.

Authors:  Shin Fukudo; Hiroshi Kaneko; Hirotada Akiho; Masahiko Inamori; Yuka Endo; Toshikatsu Okumura; Motoyori Kanazawa; Takeshi Kamiya; Ken Sato; Toshimi Chiba; Kenji Furuta; Shigeru Yamato; Tetsuo Arakawa; Yoshihide Fujiyama; Takeshi Azuma; Kazuma Fujimoto; Tetsuya Mine; Soichiro Miura; Yoshikazu Kinoshita; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2014-12-12       Impact factor: 7.527

10.  Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.

Authors:  Shin Fukudo; Yoshikazu Kinoshita; Toshikatsu Okumura; Motoko Ida; Hiraku Akiho; Yoshihiro Nakashima; Akito Nishida; Ken Haruma
Journal:  Gastroenterology       Date:  2015-11-06       Impact factor: 22.682

View more
  1 in total

Review 1.  Sex-Gender Differences in Irritable Bowel Syndrome.

Authors:  Young Sun Kim; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2018-10-01       Impact factor: 4.924

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.